ResearcherSichuan UniversityNo recent work listed

Hongmei Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2866-8227; OpenAlex author ID A5075231449. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2020: 1 paper · 2021: 1 paper

Papers 2

PKCι regulates the expression of PDL1 through multiple pathways to modulate immune suppression of pancreatic cancer cells. Co-author DOI 10.1016/j.cellsig.2021.110115 ↗
Mu-KRAS attenuates Hippo signaling pathway through PKCι to sustain the growth of pancreatic cancer. First author DOI 10.1002/jcp.28981 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Tongbo Zhu · 2 shared papers, 2020–2021 · strength 0.26
- Paper PKCι regulates the expression of PDL1 through multiple pathways to modulate immune suppression of pancreatic cancer cel… DOI 10.1016/j.cellsig.2021.110115 ↗
- Paper Mu-KRAS attenuates Hippo signaling pathway through PKCι to sustain the growth of pancreatic cancer. DOI 10.1002/jcp.28981 ↗
Sijia Weng · 1 shared paper, 2021 · strength 0.15
- Paper PKCι regulates the expression of PDL1 through multiple pathways to modulate immune suppression of pancreatic cancer cel… DOI 10.1016/j.cellsig.2021.110115 ↗
Peipei Wang · 1 shared paper, 2020 · strength 0.11
- Paper Mu-KRAS attenuates Hippo signaling pathway through PKCι to sustain the growth of pancreatic cancer. DOI 10.1002/jcp.28981 ↗
Changyan Chen · 1 shared paper, 2020 · strength 0.11
- Paper Mu-KRAS attenuates Hippo signaling pathway through PKCι to sustain the growth of pancreatic cancer. DOI 10.1002/jcp.28981 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.